Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

InFUSing antisense oligonucleotides for treating ALS.

Trends in molecular medicine - 1 Apr 2022

Codron Philippe, Cassereau Julien, Vourc'h Patrick

Abstract excerpt

The question of a loss or toxic gain of function in FUS-related amyotrophic lateral sclerosis is still debated. Recently, Korobeynikov et al. argued that FUS mutations lead to a gain of function and showed that lowering wild-type and mutant FUS levels could be a promising therapeutic strategy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to DNA-Binding Proteins
Share to FUS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oligonucleotides, Antisense

Share to RNA-Binding Protein FUS

Source

Identifiers

PMID: 35246398
DOI: 10.1016/j.molmed.2022.02.006

Genes

FUS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

InFUSing antisense oligonucleotides for treating ALS.PMID 35246398Read ↗

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosisSemantic proximity Read ↗

Allele-Selective Thiomorpholino Antisense Oligonucleotides as a Therapeutic Approach for Fused-in-Sarcoma Amyotrophic Lateral Sclerosis.Semantic proximity Read ↗

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.Semantic proximity Read ↗

The sense of antisense therapies in ALSSemantic proximity Read ↗

Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targetsSemantic proximity Read ↗

Antisense Oligonucleotides for the Study and Treatment of ALSSemantic proximity Read ↗

Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene TherapySemantic proximity Read ↗

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen.Semantic proximity Read ↗

Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD DiseasesSemantic proximity Read ↗

Gene Therapy in Amyotrophic Lateral SclerosisSemantic proximity Read ↗

DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseasesSemantic proximity Read ↗

Tofersen and other antisense oligonucleotides in ALSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.